Remifentanil
Clinical data | |
---|---|
Trade names | Ultiva |
Other names | methyl 1-(2-methoxycarbonylethyl)-4-(phenyl-propanoyl-amino)-piperidine-4-carboxylate |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Intravenous | |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 0 |
Protein binding | 70% (bound to plasma proteins) |
Metabolism | cleaved by non-specific plasma and tissue esterases |
Elimination half-life | 1-20 minutes |
Identifiers | |
| |
JSmol) | |
Melting point | 5 °C (41 °F) |
| |
| |
(verify) |
Remifentanil, marketed under the brand name Ultiva is a potent, short-acting synthetic
Clinical use
Remifentanil is used as an opioid analgesic that has a rapid onset and rapid recovery time.[2] It has been used effectively during craniotomies,[3] spinal surgery,[4] cardiac surgery,[5] and gastric bypass surgery.[6] While opiates function similarly, with respect to analgesia, the pharmacokinetics of remifentanil[7] allows for quicker post-operative recovery.[8]
Administration
It is administered in the form remifentanil hydrochloride and in adults is given as an
Remifentanil can be administered as part of an anesthesia technique called TIVA (
Remifentanil's short context-sensitive half-life makes it ideal for intense pain of short duration. As such, it has been used for analgesia in labor successfully; however, it is not as effective as epidural analgesia.[12]
In combination with propofol, remifentanil is used for anesthesia of patients undergoing electroconvulsive therapy.[13]
Metabolism
Remifentanil is considered a metabolic soft drug,[14] one that is rapidly metabolized to an inactive form. Unlike other synthetic opioids which are hepatically metabolized, remifentanil has an ester linkage which undergoes rapid hydrolysis by non-specific tissue and plasma esterases. This means that accumulation does not occur with remifentanil and its context-sensitive half-life remains at 4 minutes after a 4-hour infusion.
Remifentanil is metabolized to a compound (remifentanil acid) which has 1/4600th the potency of the parent compound.[15]
Due to its quick metabolism and short effects, remifentanil has opened up new possibilities in anesthesia. When remifentanil is used together with a hypnotic (i.e. one that produces sleep) it can be used in relative high doses. This is because remifentanil is rapidly eliminated from the blood plasma on termination of the remifentanil infusion; hence the effects of the drug quickly dissipate even after very long infusions. Owing to synergism between remifentanil and hypnotic drugs (such as propofol) the dose of the hypnotic can be substantially reduced.[16] This leads often to more hemodynamic stability during surgery and a quicker post-operative recovery time.
Side-effects
Remifentanil is a specific
The most common side effects reported by patients receiving this medication are a sense of extreme "dizziness" (often short lived, a common side effect of other fast-acting synthetic phenylpiperidine narcotics such as
Because pruritus is partially due to excessive serum histamine levels, antihistamines such as diphenhydramine (Benadryl) are often co-administered. This is done with care, however, as excessive sedation may occur.
Nausea can occur as a side effect of remifentanil, however, it is usually transient in nature due to the drug's short half-life which rapidly removes it from the patient's circulation once the infusion is terminated.
Potency
Comparing its analgesia-sedation effect in ventilated patients, remifentanil may be superior to morphine[17] but not to fentanyl.[18]
Circumventing naltrexone
Remifentanil has been used with some success to circumvent naltrexone in patients who are in need of pain management.
Abuse potential
Remifentanil, being a μ-receptor agonist, functions like other μ-receptor agonists, such as morphine and codeine; it can cause euphoria and has the potential for abuse.[19][20] However, due to its rapid metabolism and short-acting half-life the likelihood of abuse is quite low. Nevertheless, there have been some documentations of remifentanil abuse.[21][22]
Development and marketing
Prior to the development of remifentanil, most short-acting hypnotics and amnestics faced issues with prolonged use, where accumulation would result in unfavorable lingering effects during post-operative recovery. Remifentanil was designed to serve as a strong anesthetic with an ultra-short and predictable duration that would not have accumulation issues.[23]
Remifentanil was patented by
Its patent ended on the 10th of September 2017.Regulation
In Hong Kong, remifentanil is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It can only be used legally by health professionals and for university research purposes. The substance can be given by pharmacists under a prescription. Anyone who supplies the substance without prescription can be fined HK$10,000 (US$1,550). The penalty for trafficking or manufacturing the substance is a HK$5,000,000 (US$775,000) fine and life imprisonment. Possession of the substance for consumption without license from the Department of Health is illegal with a HK$1,000,000 (US$155,000) fine and/or 7 years of jail time.
Remifentanil is a Schedule II narcotic controlled substance in the United States with a DEA ACSCN of 9739 and a 2013 annual aggregate manufacturing quota of 3,750 grams, unchanged from the prior year.
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ "Remifentanil, IV opioid analgesic, Remi | Ultiva". www.ultiva.com. Retrieved 2015-11-30.
- PMID 10553851.
- S2CID 45361690.
- PMID 16865075.
- PMID 17606479.
- PMID 8982900.
- PMID 9066316.
- PMID 14722167.
- ^ "Remifentanil Actavis" (in Swedish). Retrieved 21 Aug 2014.
- PMID 31230994.
- S2CID 4844447.
- PMID 24398757.
- S2CID 25119421.
- PMID 9103501.
- ^ S2CID 265900417.
- S2CID 17192694.
- PMID 21165734.
- PMID 2198785.
- S2CID 21623038.
- PMID 11106130.
- PMID 19917624.
- ISBN 9780471398486.
- ^ US 5866591, Gatlin LA, Heiman SA, Lewis JS, "Stable formulations of remifentanil", issued 2 February 1999
- ^ Orange book: approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: US Food and Drug Administration. 2010.
External links
- "Remifentanil". Drug Information Portal. U.S. National Library of Medicine.
- "Remifentanil Hydrochloride". Drug Information Portal. U.S. National Library of Medicine.